4D Molecular Therapeutics, Inc. (FDMT)
10.80
-1.05
(-8.86%)
USD |
NASDAQ |
Oct 23, 16:00
10.78
-0.02
(-0.23%)
After-Hours: 20:00
4D Molecular Therapeutics Debt to Equity Ratio : 0.0962 for June 30, 2026
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.0962 |
| March 31, 2026 | 0.0454 |
| December 31, 2025 | 0.0423 |
| September 30, 2025 | 0.0603 |
| June 30, 2025 | 0.0548 |
| March 31, 2025 | 0.0508 |
| December 31, 2024 | 0.0482 |
| September 30, 2024 | 0.0449 |
| June 30, 2024 | 0.0232 |
| March 31, 2024 | 0.0236 |
| September 30, 2023 | 0.0459 |
| June 30, 2023 | 0.0481 |
| March 31, 2023 | 0.0717 |
| Date | Value |
|---|---|
| December 31, 2022 | 0.0697 |
| September 30, 2022 | 0.0658 |
| June 30, 2022 | 0.0624 |
| March 31, 2022 | 0.0568 |
| December 31, 2021 | 0.0515 |
| September 30, 2021 | 0.00 |
| June 30, 2021 | 0.00 |
| March 31, 2021 | 0.00 |
| September 30, 2020 | |
| June 30, 2020 | |
| March 31, 2020 | |
| December 31, 2019 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Agenus, Inc. | -1.458 |
| Amgen, Inc. | 4.903 |
| Anika Therapeutics, Inc. | 0.1839 |
| BioCryst Pharmaceuticals, Inc. | -1.842 |
| Imunon, Inc. | 1.873 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 492.62M |
| Total Liabilities (Quarterly) | 84.96M |
| Shareholders Equity (Quarterly) | 407.66M |
| Current Ratio | 8.033 |
| Net Debt Paydown Yield | -0.42% |